MILAGROS SAMANIEGO-PICOTA
- Type
- Physician · Allopathic & Osteopathic Physicians / Internal Medicine / Nephrology
- Where
- ROSWELL, NM
- NPI
- 1790746154
- Received
- $10,884 in 31 records, 2019 to 2025
- As principal investigator
- $113,537 of research payments to others in 168 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 21 | $437 |
| 2024 | General payment | 1 | $17 |
| 2023 | General payment | 3 | $182 |
| 2022 | General payment | 3 | $1,095 |
| 2021 | General payment | 2 | $6,652 |
| 2019 | General payment | 1 | $2,500 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $4,080 | 2021 |
| SANOFI-AVENTIS U.S. LLC | 2 | $2,675 | 2021–2023 |
| Astellas Pharma US Inc | 1 | $2,500 | 2019 |
| CSL Behring | 1 | $912 | 2022 |
| Bayer Healthcare Pharmaceuticals Inc. | 10 | $205 | 2024–2025 |
| Novo Nordisk Inc | 2 | $128 | 2022–2025 |
| Novartis Pharmaceuticals Corporation | 2 | $79 | 2023 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $77 | 2022 |
| ANI Pharmaceuticals, Inc. | 3 | $66 | 2025 |
| Amgen Inc. | 2 | $46 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $40 | 2025 |
| AstraZeneca Pharmaceuticals LP | 2 | $28 | 2025 |
| Mallinckrodt Hospital Products Inc. | 1 | $23 | 2025 |
| GlaxoSmithKline, LLC. | 1 | $21 | 2025 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Consulting Fee | 2 | $6,580 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 1 | $2,572 |
| Travel and Lodging | 1 | $912 |
| Food and Beverage | 27 | $820 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-15 | ANI Pharmaceuticals, Inc. | $23 | Food and Beverage | In-kind items and services | PURIFIED CORTROPHIN GEL Drug, Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | 2025 | |
| 2025-12-08 | Bayer Healthcare Pharmaceuticals Inc. | $23 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-11-13 | Bayer Healthcare Pharmaceuticals Inc. | $16 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-11-05 | Boehringer Ingelheim Pharmaceuticals, Inc. | $22 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2025 | |
| 2025-10-14 | Bayer Healthcare Pharmaceuticals Inc. | $24 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-10-01 | Bayer Healthcare Pharmaceuticals Inc. | $16 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-09-24 | ANI Pharmaceuticals, Inc. | $15 | Food and Beverage | In-kind items and services | PURIFIED CORTROPHIN GEL Drug, Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | 2025 | |
| 2025-08-07 | Bayer Healthcare Pharmaceuticals Inc. | $22 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-07-28 | GlaxoSmithKline, LLC. | $21 | Food and Beverage | In-kind items and services | BENLYSTA Biological, IMMUNOLOGY | 2025 | |
| 2025-07-22 | ANI Pharmaceuticals, Inc. | $26 | Food and Beverage | In-kind items and services | PURIFIED CORTROPHIN GEL Drug, Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | 2025 | |
| 2025-07-21 | Mallinckrodt Hospital Products Inc. | $23 | Food and Beverage | In-kind items and services | ACTHAR Biological, IMMUNOLOGY | 2025 | |
| 2025-06-17 | Boehringer Ingelheim Pharmaceuticals, Inc. | $18 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2025 | |
| 2025-05-29 | Bayer Healthcare Pharmaceuticals Inc. | $24 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-04-10 | Bayer Healthcare Pharmaceuticals Inc. | $15 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-04-07 | AstraZeneca Pharmaceuticals LP | $14 | Food and Beverage | In-kind items and services | FARXIGA Drug, Cardiovascular and Metabolism | 2025 | |
| 2025-03-06 | Amgen Inc. | $22 | Food and Beverage | In-kind items and services | TAVNEOS Drug, Inflammation | 2025 | |
| 2025-02-27 | Novo Nordisk Inc | $23 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2025 | |
| 2025-02-20 | Bayer Healthcare Pharmaceuticals Inc. | $27 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-02-03 | AstraZeneca Pharmaceuticals LP | $13 | Food and Beverage | In-kind items and services | FARXIGA Drug, Cardiovascular and Metabolism | 2025 | |
| 2025-01-31 | Bayer Healthcare Pharmaceuticals Inc. | $18 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-01-09 | Amgen Inc. | $24 | Food and Beverage | In-kind items and services | TAVNEOS Drug, Inflammation | 2025 | |
| 2024-11-22 | Bayer Healthcare Pharmaceuticals Inc. | $17 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-renal | 2024 | |
| 2023-06-02 | SANOFI-AVENTIS U.S. LLC | $103 | Food and Beverage | In-kind items and services | THYMOGLOBULIN Biological, Oncology | 2023 | |
| 2023-04-18 | Novartis Pharmaceuticals Corporation | $42 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-01-20 | Novartis Pharmaceuticals Corporation | $36 | Food and Beverage | In-kind items and services | 2023 | ||
| 2022-11-28 | Takeda Pharmaceuticals U.S.A., Inc. | $77 | Food and Beverage | In-kind items and services | 2022 | ||
| 2022-11-15 | Novo Nordisk Inc | $105 | Food and Beverage | In-kind items and services | 2022 | ||
| 2022-08-17 | CSL Behring | $912 | Travel and Lodging | In-kind items and services | 2022 | ||
| 2021-10-13 | Otsuka Pharmaceutical Development & Commercialization, Inc. | $4,080 | Consulting Fee | Cash or cash equivalent | 2021 | ||
| 2021-06-24 | SANOFI-AVENTIS U.S. LLC | $2,572 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | THYMOGLOBULIN Biological, Oncology | 2021 | |
| 2019-04-26 | Astellas Pharma US Inc | $2,500 | Consulting Fee | Cash or cash equivalent | 2019 |
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2024-05-14 | CSL Behring | Henry Ford Hospital | $400 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2024 |
| 2024-02-08 | CSL Behring | Henry Ford Hospital | $200 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2024 |
| 2024-01-19 | CSL Behring | Henry Ford Hospital | $400 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2024 |
| 2023-12-19 | CSL Behring | Henry Ford Hospital | $1,044 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2023 |
| 2023-12-08 | CSL Behring | Henry Ford Hospital | $968 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2023 |
| 2023-11-17 | CSL Behring | Henry Ford Hospital | $961 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2023 |
| 2023-11-16 | CSL Behring | Henry Ford Hospital | $36 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2023 |
| 2023-11-09 | CSL Behring | Henry Ford Hospital | $844 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2023 |
| 2023-10-19 | CSL Behring | Henry Ford Hospital | $844 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2023 |
| 2023-10-13 | CSL Behring | Henry Ford Hospital | $968 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2023 |
| 2023-10-12 | CSL Behring | Henry Ford Hospital | $30 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2023 |
| 2023-10-12 | CSL Behring | Henry Ford Hospital | $18 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2023 |
| 2023-10-12 | CSL Behring | Henry Ford Hospital | $26 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2023 |
| 2023-10-12 | CSL Behring | Henry Ford Hospital | $156 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2023 |
| 2023-10-12 | CSL Behring | Henry Ford Hospital | $130 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2023 |
| 2023-10-12 | CSL Behring | Henry Ford Hospital | $18 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2023 |
| 2023-10-12 | CSL Behring | Henry Ford Hospital | $36 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2023 |
| 2023-09-21 | CSL Behring | Henry Ford Hospital | $844 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2023 |
| 2023-09-21 | CSL Behring | Henry Ford Hospital | $844 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2023 |
| 2023-09-01 | CSL Behring | Henry Ford Hospital | $980 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2023 |
| 2023-08-17 | CSL Behring | Henry Ford Hospital | $844 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2023 |
| 2023-08-03 | CSL Behring | Henry Ford Hospital | $844 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2023 |
| 2023-07-31 | CSL Behring | Henry Ford Hospital | $36 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2023 |
| 2023-07-26 | CSL Behring | Henry Ford Hospital | $980 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2023 |
| 2023-07-04 | CSL Behring | Henry Ford Hospital | $844 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2023 |
| 2023-06-28 | CSL Behring | Henry Ford Hospital | $2,412 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2023 |
| 2023-05-24 | CSL Behring | Henry Ford Hospital | $844 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2023 |
| 2023-05-19 | CSL Behring | Henry Ford Hospital | $90 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2023 |
| 2023-05-19 | CSL Behring | Henry Ford Hospital | $36 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2023 |
| 2023-05-19 | CSL Behring | Henry Ford Hospital | $54 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2023 |
| 2023-05-19 | CSL Behring | Henry Ford Hospital | $72 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2023 |
| 2023-05-19 | CSL Behring | Henry Ford Hospital | $72 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2023 |
| 2023-05-19 | CSL Behring | Henry Ford Hospital | $72 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2023 |
| 2023-05-19 | CSL Behring | Henry Ford Hospital | $126 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2023 |
| 2023-05-19 | CSL Behring | Henry Ford Hospital | $14 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2023 |
| 2023-05-19 | CSL Behring | Henry Ford Hospital | $144 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2023 |
| 2023-05-19 | CSL Behring | Henry Ford Hospital | $216 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2023 |
| 2023-05-19 | CSL Behring | Henry Ford Hospital | $72 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2023 |
| 2023-05-11 | CSL Behring | Henry Ford Hospital | $567 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2023 |
| 2023-04-27 | CSL Behring | Henry Ford Hospital | $36 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2023 |
| 2023-04-27 | CSL Behring | Henry Ford Hospital | $36 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2023 |
| 2023-04-27 | CSL Behring | Henry Ford Hospital | $18 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2023 |
| 2023-04-27 | CSL Behring | Henry Ford Hospital | $18 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2023 |
| 2023-04-27 | CSL Behring | Henry Ford Hospital | $54 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2023 |
| 2023-04-27 | CSL Behring | Henry Ford Hospital | $36 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2023 |
| 2023-04-27 | CSL Behring | Henry Ford Hospital | $18 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2023 |
| 2023-04-27 | CSL Behring | Henry Ford Hospital | $13 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2023 |
| 2023-04-27 | CSL Behring | Henry Ford Hospital | $104 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2023 |
| 2023-04-27 | CSL Behring | Henry Ford Hospital | $52 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2023 |
| 2023-04-26 | CSL Behring | Henry Ford Hospital | $968 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2023 |
| 2023-04-06 | CSL Behring | Henry Ford Hospital | $1,455 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2023 |
| 2023-03-16 | CSL Behring | Henry Ford Hospital | $961 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2023 |
| 2023-03-09 | CSL Behring | Henry Ford Hospital | $888 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2023 |
| 2023-02-16 | CSL Behring | Henry Ford Hospital | $844 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2023 |
| 2023-02-02 | CSL Behring | Henry Ford Hospital | $961 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2023 |
| 2023-01-20 | CSL Behring | Henry Ford Hospital | $1,004 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2023 |
| 2023-01-16 | CSL Behring | Henry Ford Hospital | $36 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2023 |
| 2023-01-16 | CSL Behring | Henry Ford Hospital | $18 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2023 |
| 2023-01-12 | CSL Behring | Henry Ford Hospital | $844 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2023 |
| 2022-12-16 | CSL Behring | Henry Ford Hospital | $2,057 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2022 |
| 2022-11-30 | CSL Behring | Henry Ford Hospital | $54 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2022 |
| 2022-11-30 | CSL Behring | Henry Ford Hospital | $54 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2022 |
| 2022-11-30 | CSL Behring | Henry Ford Hospital | $36 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2022 |
| 2022-11-30 | CSL Behring | Henry Ford Hospital | $18 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2022 |
| 2022-11-30 | CSL Behring | Henry Ford Hospital | $30 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2022 |
| 2022-11-30 | CSL Behring | Henry Ford Hospital | $52 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2022 |
| 2022-11-30 | CSL Behring | Henry Ford Hospital | $26 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2022 |
| 2022-11-30 | CSL Behring | Henry Ford Hospital | $36 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2022 |
| 2022-11-30 | CSL Behring | Henry Ford Hospital | $36 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2022 |
| 2022-11-17 | CSL Behring | Henry Ford Hospital | $567 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2022 |
| 2022-11-03 | CSL Behring | Henry Ford Hospital | $1,052 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2022 |
| 2022-10-20 | CSL Behring | Henry Ford Hospital | $1,716 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2022 |
| 2022-10-13 | CSL Behring | Henry Ford Hospital | $567 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2022 |
| 2022-09-28 | CSL Behring | Henry Ford Hospital | $2,472 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2022 |
| 2022-09-22 | CSL Behring | Henry Ford Hospital | $1,716 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2022 |
| 2022-09-15 | CSL Behring | Henry Ford Hospital | $888 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2022 |
| 2022-09-06 | CSL Behring | Henry Ford Hospital | $18 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2022 |
| 2022-09-06 | CSL Behring | Henry Ford Hospital | $18 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2022 |
| 2022-09-06 | CSL Behring | Henry Ford Hospital | $18 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2022 |
| 2022-09-06 | CSL Behring | Henry Ford Hospital | $26 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2022 |
| 2022-09-06 | CSL Behring | Henry Ford Hospital | $36 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2022 |
| 2022-09-06 | CSL Behring | Henry Ford Hospital | $18 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2022 |
| 2022-08-01 | CSL Behring | Henry Ford Hospital | $104 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2022 |
| 2022-08-01 | CSL Behring | Henry Ford Hospital | $26 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2022 |
| 2022-08-01 | CSL Behring | Henry Ford Hospital | $36 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2022 |
| 2022-08-01 | CSL Behring | Henry Ford Hospital | $36 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2022 |
| 2022-08-01 | CSL Behring | Henry Ford Hospital | $36 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2022 |
| 2022-08-01 | CSL Behring | Henry Ford Hospital | $18 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2022 |
| 2022-08-01 | CSL Behring | Henry Ford Hospital | $36 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2022 |
| 2022-08-01 | CSL Behring | Henry Ford Hospital | $30 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2022 |
| 2022-07-27 | CSL Behring | Henry Ford Hospital | $1,791 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2022 |
| 2022-07-21 | CSL Behring | Henry Ford Hospital | $1,192 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2022 |
| 2022-06-16 | CSL Behring | Henry Ford Hospital | $903 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2022 |
| 2022-06-02 | CSL Behring | Henry Ford Hospital | $903 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2022 |
| 2022-05-25 | CSL Behring | Henry Ford Hospital | $1,192 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2022 |
| 2022-05-19 | CSL Behring | Henry Ford Hospital | $888 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2022 |
| 2022-05-02 | CSL Behring | Henry Ford Hospital | $54 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2022 |
| 2022-04-21 | CSL Behring | Henry Ford Hospital | $903 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2022 |
| 2022-04-11 | CSL Behring | Henry Ford Hospital | $1,048 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2022 |
| 2022-03-30 | CSL Behring | Henry Ford Hospital | $30 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2022 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Roswell, NM, county Chaves County, NM, state New Mexico; placed by its city name.
| Measure | Place (city or town) Roswell, NM | County Chaves County, NM | State New Mexico |
|---|---|---|---|
| Population B01003 | 47,638 | 64,217 | 2,120,246 |
| Population, 2020 census P1 | 48,422 | 65,157 | 2,117,522 |
| Median age B01002 | 37.1 | 37.2 | 39.4 |
| Under 18 B01001 | 24.7% | 24.6% | 21.7% |
| 65 and over B01001 | 16.0% | 16.5% | 19.3% |
| Households B11001 | 17,838 | 23,712 | 837,414 |
| Foreign born B05002 | 11.2% | 11.3% | 9.4% |
| Median household income B19013 | $51,583 | $52,938 | $64,059 |
| Median family income B19113 | $60,225 | $62,180 | $79,556 |
| Per capita income B19301 | $29,093 | $28,881 | $36,218 |
| Poverty rate B17001 | 26.0% | 24.3% | 17.8% |
| Unemployment rate B23025 | 5.0% | 5.0% | 6.0% |
| Civilian labor force B23025 | 20,645 | 28,005 | 975,902 |
| Mean commute (minutes) B08013 | 18.2 | 19.3 | 23.5 |
| Bachelor's degree or higher B15003 | 18.6% | 17.9% | 31.0% |
| Housing units B25001 | 19,994 | 26,864 | 956,964 |
| Owner-occupied B25003 | 68.6% | 71.3% | 70.0% |
| Renters B25003 | 31.4% | 28.7% | 30.0% |
| Median home value B25077 | $152,600 | $156,400 | $248,100 |
| Median gross rent B25064 | $876 | $867 | $1,067 |
| White, not Hispanic B03002 | 33.6% | 36.1% | 36.0% |
| Black B03002 | 1.8% | 1.5% | 1.8% |
| Hispanic or Latino B03002 | 60.7% | 58.4% | 48.4% |
| Asian B03002 | 1.4% | 1.1% | 1.6% |
| American Indian and Alaska Native B03002 | 0.4% | 0.6% | 8.5% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Roswell, NM.
Comments